GO:0004357 glutamate-cysteine ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004357 describes the ATP-dependent ligation of L-cysteine and L-glutamate to form L-gamma-glutamyl-L-cysteine, the first and rate-limiting step of glutathione biosynthesis.
• The reaction is catalyzed by glutamate-cysteine ligase (GCL), a heterodimer composed of a catalytic subunit (GCLC) and a modifier subunit (GCLM).
• GCL activity is essential for maintaining cellular glutathione (GSH) levels, protecting cells from oxidative stress and ferroptosis.
• Non-canonical GCL activity, independent of cysteine availability, can protect cancer cells from ferroptosis.
• GCL is regulated at multiple levels, including transcriptional, post-translational, and metabolic control, and is a target for cancer therapy [3,5].
• Dysregulation of GCL is implicated in cancer chemoresistance, neurodegeneration, and age-related decline in glutathione [6,7].
Description
Glutamate-cysteine ligase (GCL) activity, encoded by the Gene Ontology term GO:0004357, catalyzes the first and rate-limiting step of glutathione (GSH) synthesis: the ATP-dependent ligation of L-cysteine and L-glutamate to form L-gamma-glutamyl-L-cysteine. This enzymatic activity is critical for maintaining cellular redox homeostasis and protecting cells from oxidative damage and ferroptosis. The GCL holoenzyme is a heterodimer consisting of a catalytic subunit (GCLC) and a modifier subunit (GCLM), which together fine-tune enzyme activity and substrate affinity. Beyond its canonical role, recent studies have revealed non-canonical GCL activity that supports cancer cell survival under metabolic stress. Understanding the molecular mechanisms, regulation, and disease relevance of GCL is essential for researchers in cancer biology, neurodegeneration, and redox biology. This article provides a comprehensive overview of GO:0004357, integrating authoritative QuickGO data with verified PubMed literature to guide experimental design and therapeutic targeting.
glutamate-cysteine ligase activity At A Glance
| GO ID | GO:0004357 |
|---|---|
| GO term | glutamate-cysteine ligase activity |
| Ontology | molecular_function |
| Synonym | gamma-glutamylcysteine synthetase activity; gamma-glutamylcysteinyl synthetase activity; gamma-glutamyl-L-cysteine synthetase activity; L-glutamate:L-cysteine gamma-ligase (ADP-forming) activity |
| Major function | Catalyzes the ATP-dependent ligation of L-cysteine and L-glutamate to form L-gamma-glutamyl-L-cysteine, the rate-limiting step in glutathione synthesis. |
| Reaction | L-cysteine + L-glutamate + ATP = L-gamma-glutamyl-L-cysteine + ADP + 2 H+ + phosphate |
| Enzyme complex | Heterodimer of GCLC (catalytic) and GCLM (modifier) subunits. |
| Cofactors | ATP, Mg2+ (implied by ATP-dependent ligase mechanism). |
| Pathway | Glutathione biosynthesis; redox homeostasis. |
What Is GO:0004357?
GO:0004357 (glutamate-cysteine ligase activity) is a molecular function defined by the catalysis of the reaction: L-cysteine + L-glutamate + ATP = L-gamma-glutamyl-L-cysteine + ADP + 2 H+ + phosphate. This activity is synonymous with gamma-glutamylcysteine synthetase activity and represents the committed step in glutathione biosynthesis.
Why Is glutamate-cysteine ligase activity Important in Cell Biology?
Glutamate-cysteine ligase activity is indispensable for cellular antioxidant defense, as it controls the rate-limiting step of glutathione synthesis. Glutathione is the most abundant non-enzymatic antioxidant in cells, and its depletion is associated with oxidative stress, ferroptosis, and numerous pathologies including cancer, neurodegeneration, and aging [1,7]. Consequently, GCL is a focal point for understanding redox regulation and for developing therapeutic strategies that modulate glutathione levels [3,5].
• Rate-limiting enzyme in glutathione synthesis, essential for redox balance.
• Protects cells from ferroptosis, a form of iron-dependent cell death.
• Implicated in cancer chemoresistance and tumor progression.
• Target for cancer therapy: inhibition of GCL sensitizes tumors to ferroptosis inducers [3,5].
• Age-related decline in GCL activity contributes to reduced glutathione and oxidative stress.
• Non-canonical GCL activity supports cancer cell survival under metabolic stress.
• Regulated by lactylation and ISG15 modification, linking metabolism and immunity [2,4].
• Potential therapeutic target in melanoma and hepatocellular carcinoma [4,5].
• Bacterial GCL enzymes provide insights into evolution and antibiotic targets.
• GCLM moonlighting function in the nucleus promotes chemoresistance.
Molecular Mechanism of glutamate-cysteine ligase activity
Substrate Binding and Catalytic Mechanism
In simple terms: The enzyme grabs glutamate and cysteine, then uses ATP energy to glue them together.
Glutamate-cysteine ligase catalyzes the ATP-dependent formation of a peptide bond between the gamma-carboxyl group of L-glutamate and the amino group of L-cysteine, yielding L-gamma-glutamyl-L-cysteine, ADP, phosphate, and protons. The reaction proceeds via a gamma-glutamyl-phosphate intermediate, and the enzyme requires Mg2+ as a cofactor. The catalytic subunit GCLC contains the active site, while GCLM modulates substrate affinity and catalytic efficiency.
Enzyme Structure and Subunit Composition
In simple terms: The enzyme is made of two parts: a big catalytic part and a smaller modifier part that tunes its activity.
The GCL holoenzyme is a heterodimer of a catalytic subunit (GCLC, ~73 kDa) and a modifier subunit (GCLM, ~31 kDa). GCLC alone is active but has lower affinity for substrates; association with GCLM lowers the Km for glutamate and increases overall activity. The subunits are encoded by separate genes, GCLC and GCLM, and their expression is coordinately regulated.
Regulation by Post-Translational Modifications
In simple terms: Chemical tags added to the enzyme can change how well it works.
GCLC activity is regulated by post-translational modifications. For example, lactylation of NSUN2 enhances GCLC-dependent glutathione synthesis, promoting ferroptosis resistance in cancer cells. ISG15 modification enhances GCL activity to suppress apoptosis in hepatocellular carcinoma. These modifications link cellular metabolism and immune signaling to GCL function.
Non-Canonical Activity and Moonlighting Functions
In simple terms: The enzyme can do more than its usual job, helping cells survive under stress.
A non-canonical GCL activity, independent of cysteine availability, protects cells from ferroptosis by maintaining glutathione levels under oxidative stress. Additionally, GCLM can translocate to the nucleus and exert a moonlighting function that promotes chemoresistance in colorectal cancer. These findings expand the functional repertoire of GCL beyond canonical glutathione synthesis.
Inhibition and Covalent Targeting
In simple terms: Drugs can block the enzyme to lower glutathione and kill cancer cells.
Covalent inhibitors of GCL have been developed to inhibit glutathione synthesis, offering a strategy to sensitize cancer cells to ferroptosis inducers. Metabolic inhibition of GCL increases dendritic cell-mediated antitumor immunity in melanoma, highlighting the immunomodulatory potential of GCL targeting.
Key Genes Involved in GO:0004357 glutamate-cysteine ligase activity
The following genes and proteins are directly involved in glutamate-cysteine ligase activity, its regulation, and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCLC | Catalytic subunit of glutamate-cysteine ligase; contains active site | Rate-limiting enzyme in glutathione synthesis; target for cancer therapy. |
| GCLM | Modifier subunit; enhances catalytic efficiency and substrate affinity | Regulates GCL activity; moonlighting function in chemoresistance. |
| NSUN2 | RNA methyltransferase; lactylation enhances GCLC-dependent glutathione synthesis | Links lactylation to ferroptosis resistance. |
| ISG15 | Ubiquitin-like modifier; enhances GCL activity | Suppresses apoptosis in hepatocellular carcinoma. |
| GPX4 | Glutathione peroxidase 4; uses glutathione to detoxify lipid peroxides | Ferroptosis regulator; GCL activity supports GPX4 function. |
| SLC7A11 | Cystine/glutamate antiporter; supplies cysteine for GCL reaction | Regulates substrate availability for GCL. |
| Nrf2 (NFE2L2) | Transcription factor; upregulates GCLC and GCLM expression | Master regulator of antioxidant response. |
| NF-κB | Transcription factor; regulates GCLC expression | Inflammatory signaling linked to GCL. |
| AP-1 | Transcription factor; regulates GCL subunit expression | Stress-responsive regulation. |
| MYXAN_RS0116880 | Glutamate-cysteine ligase in Myxococcus xanthus | Bacterial model for GCL evolution. |
| MYXAN_RS0116875 | Glutathione synthetase in Myxococcus xanthus | Bacterial glutathione synthesis. |
| GSS | Glutathione synthetase; second step of glutathione synthesis | Downstream of GCL. |
| GGT | Gamma-glutamyl transpeptidase; glutathione catabolism | Regulates glutathione turnover. |
| MRP1 (ABCC1) | Multidrug resistance protein; exports glutathione conjugates | Chemoresistance linked to GCL. |
| BCL-2 | Anti-apoptotic protein; interacts with GCL pathway | Apoptosis regulation. |
| Caspase-3 | Executioner caspase; apoptosis marker | ISG15-GCL axis suppresses apoptosis. |
| mTOR | Kinase; regulates metabolism and GCL expression | Links nutrient signaling to glutathione. |
| ATF4 | Transcription factor; induces GCLC under stress | Integrated stress response. |
How Is glutamate-cysteine ligase activity Regulated?
Glutamate-cysteine ligase activity is regulated at multiple levels. Transcriptionally, GCLC and GCLM are induced by Nrf2, NF-κB, and AP-1 in response to oxidative stress. Post-translational modifications, such as lactylation and ISG15 conjugation, modulate GCL activity [2,4]. Metabolically, substrate availability (cysteine and glutamate) and ATP levels influence enzyme flux. Additionally, GCLM can translocate to the nucleus and exert non-canonical functions. These regulatory layers ensure precise control of glutathione synthesis under varying physiological conditions.
glutamate-cysteine ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCLC | Cancer chemoresistance; ferroptosis | GCLC knockout cancer cell lines; ferroptosis induction assays [1,3]. |
| GCLM | Colorectal cancer chemoresistance | GCLM knockout or nuclear-localization mutants in HCT116 cells. |
| NSUN2 | Ferroptosis resistance in cancer | NSUN2 lactylation mutants; GCLC expression analysis. |
| ISG15 | Hepatocellular carcinoma; apoptosis | ISG15 knockout or overexpression in HCC cell lines. |
| GPX4 | Ferroptosis; oxidative stress | GPX4 knockout cells; lipid peroxidation assays. |
Cancer and Chemoresistance
GCL activity is often upregulated in cancer cells to maintain glutathione levels and resist oxidative stress and chemotherapy. Nuclear GCLM promotes chemoresistance in colorectal cancer through a moonlighting function. Inhibition of GCL sensitizes cancer cells to ferroptosis inducers, offering a therapeutic strategy [3,5]. In melanoma, metabolic inhibition of GCL increases dendritic cell-mediated antitumor immunity.
Ferroptosis and Oxidative Stress
GCL activity protects cells from ferroptosis by sustaining glutathione synthesis. Non-canonical GCL activity, independent of cysteine availability, is critical for ferroptosis protection under metabolic stress. NSUN2 lactylation enhances GCLC-dependent glutathione synthesis, driving ferroptosis resistance in cancer cells.
Neurodegeneration and Aging
Age-related decline in GCL activity contributes to reduced cellular glutathione and increased oxidative stress, which is implicated in neurodegeneration. Therapeutic potential of gamma-glutamylcysteine, the product of GCL, has been explored for restoring glutathione levels in aging.
Liver Disease and Hepatocellular Carcinoma
ISG15 enhances GCL activity to suppress apoptosis in high-fat-diet-promoted hepatocellular carcinoma, linking GCL to liver cancer progression. GCL dysregulation may contribute to liver disease pathogenesis through altered redox balance.
From glutamate-cysteine ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GCLC loss sensitize cancer cells to ferroptosis? | GCLC knockout cell lines (e.g., A549, HCT116) [1,3]. |
| How does GCLM nuclear localization affect chemoresistance? | GCLM point mutants (nuclear localization signal) or knockout. |
| Does NSUN2 lactylation regulate GCLC-dependent glutathione synthesis? | NSUN2 lactylation-deficient knock-in cells. |
| Can ISG15 modification enhance GCL activity? | ISG15 overexpression or knockout in HCC cells. |
| What is the effect of GCL inhibition on antitumor immunity? | GCL inhibitor-treated melanoma cells co-cultured with dendritic cells. |
| How does bacterial GCL differ from human? | Myxococcus xanthus GCL knockout and complementation. |
How to Study the glutamate-cysteine ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | GCL catalytic activity | Kinetic studies, inhibitor screening. |
| Glutathione recycling assay | Total glutathione levels | Redox status assessment. |
| CRISPR knockout | Loss of GCL subunit function | Ferroptosis sensitivity, chemoresistance [1,6]. |
| LC-MS/MS | L-gamma-glutamyl-L-cysteine and post-translational modifications | Metabolomics, PTM analysis [2,4]. |
| Western blot | GCLC/GCLM protein levels | Expression analysis. |
| qRT-PCR | GCLC/GCLM mRNA levels | Transcriptional regulation. |
| Immunofluorescence | Subcellular localization of GCLM | Nuclear moonlighting function. |
| Ferroptosis assays | Cell death, lipid peroxidation | GCL protection against ferroptosis. |
Enzymatic Activity Assays
Glutamate-cysteine ligase activity can be measured spectrophotometrically by coupling the reaction to pyruvate kinase and lactate dehydrogenase, monitoring NADH oxidation at 340 nm. Alternatively, HPLC or LC-MS can quantify L-gamma-glutamyl-L-cysteine production.
Glutathione Quantification
Total glutathione levels are measured using enzymatic recycling assays (e.g., Tietze assay) or HPLC. GCL activity is inferred from glutathione levels and sensitivity to GCL inhibitors [1,7].
Genetic Knockout and Knockdown
CRISPR-Cas9 knockout of GCLC or GCLM, or siRNA knockdown, is used to assess loss of GCL activity and its consequences on glutathione, ferroptosis, and chemoresistance [1,6].
Proteomics and Post-Translational Modification Analysis
Mass spectrometry-based proteomics can identify post-translational modifications on GCLC/GCLM, such as lactylation or ISG15 conjugation, and quantify their effects on activity [2,4].
How CRISPR Can Be Used to Study GO:0004357 glutamate-cysteine ligase activity
Knockout
CRISPR-Cas9 knockout of GCLC or GCLM is used to abolish GCL activity, leading to glutathione depletion and increased sensitivity to oxidative stress and ferroptosis [1,6]. These models are valuable for studying the role of GCL in cancer chemoresistance and neurodegeneration.
Point Mutation
Point mutations can be introduced into GCLC or GCLM to dissect catalytic residues, substrate binding sites, or post-translational modification sites (e.g., lactylation or ISG15 conjugation sites) [2,4]. Such models help define structure-function relationships.
Knock-in
Knock-in of tagged GCLC or GCLM (e.g., GFP, FLAG) allows for live-cell imaging, immunoprecipitation, and proteomic analysis of GCL complexes. Knock-in of disease-associated variants can model human pathologies.
Overexpression
Overexpression of GCLC or GCLM via lentiviral or CRISPR activation (CRISPRa) increases GCL activity and glutathione levels, protecting cells from oxidative stress and ferroptosis [1,4]. This approach is useful for gain-of-function studies.
How EDITGENE Supports glutamate-cysteine ligase activity Research
Researchers studying glutamate-cysteine ligase activity-related genes often need to determine whether a candidate gene is causally involved in glutathione synthesis, ferroptosis, or chemoresistance. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for glutamate-cysteine ligase activity research.
Frequently Asked Questions About glutamate-cysteine ligase activity
What is glutamate-cysteine ligase activity?
It is the enzymatic activity (GO:0004357) that catalyzes the ATP-dependent ligation of L-cysteine and L-glutamate to form L-gamma-glutamyl-L-cysteine, the rate-limiting step in glutathione synthesis.
What genes are involved in glutamate-cysteine ligase activity?
The main genes are GCLC (catalytic subunit) and GCLM (modifier subunit), which form the GCL holoenzyme.
What is the role of GCLC in glutathione synthesis?
GCLC contains the active site and catalyzes the ligation reaction; its expression and activity determine the rate of glutathione synthesis.
How is glutamate-cysteine ligase activity regulated?
It is regulated transcriptionally by Nrf2, NF-κB, and AP-1, and post-translationally by lactylation and ISG15 modification [2,4,7].
What diseases are associated with glutamate-cysteine ligase dysfunction?
Cancer chemoresistance, ferroptosis-related pathologies, neurodegeneration, and age-related oxidative stress [1,6,7].
How can I measure glutamate-cysteine ligase activity?
Enzymatic assays coupled to NADH oxidation, or by quantifying glutathione levels using recycling assays.
What is the non-canonical activity of glutamate-cysteine ligase?
A cysteine-independent activity that protects cells from ferroptosis under metabolic stress.
Can CRISPR be used to study glutamate-cysteine ligase?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect GCL function [1,6].
What is the relationship between GCL and ferroptosis?
GCL maintains glutathione levels, which are required for GPX4 to detoxify lipid peroxides; loss of GCL sensitizes cells to ferroptosis.
How does GCLM contribute to chemoresistance?
GCLM can translocate to the nucleus and exert a moonlighting function that promotes chemoresistance in colorectal cancer.
Conclusion
Glutamate-cysteine ligase activity (GO:0004357) is a fundamental enzymatic function that controls the rate-limiting step of glutathione synthesis, protecting cells from oxidative stress and ferroptosis. Its dysregulation is implicated in cancer chemoresistance, neurodegeneration, and aging. Recent discoveries of non-canonical activities and post-translational regulation highlight the complexity of GCL biology. CRISPR-based models are invaluable for dissecting these mechanisms and developing therapeutic strategies. EDITGENE offers comprehensive services to support research on GCL and related pathways.
References
- 1. Kang YP et al.. 2021. Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis.. Cell Metab 33(1):174-189.e7 PMID: 33357455
- 2. Niu K et al.. 2025. NSUN2 lactylation drives cancer cell resistance to ferroptosis through enhancing GCLC-dependent glutathione synthesis.. Redox Biol 79:103479 PMID: 39742570
- 3. Zhang LH et al.. 2023. Covalent Targeting of Glutamate Cysteine Ligase to Inhibit Glutathione Synthesis.. Chembiochem 24(23):e202300371 PMID: 37756477
- 4. Liu X et al.. 2025. ISG15 Enhances the Activity of γ-Glutamate Cysteine Ligase to Suppress Apoptosis in High Fat Diet-Promoted Hepatocellular Carcinoma.. Adv Sci (Weinh) 12(19):e2416401 PMID: 40126377
- 5. Dieckmann SM et al.. 2026. Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.. J Immunother Cancer 14(6) PMID: 42379703
- 6. Lin JF et al.. 2025. Nucleus-translocated GCLM promotes chemoresistance in colorectal cancer through a moonlighting function.. Nat Commun 16(1):263 PMID: 39747101
- 7. Ferguson G et al.. 2016. Glutamate cysteine ligase and the age-related decline in cellular glutathione: The therapeutic potential of γ-glutamylcysteine.. Arch Biochem Biophys 593:12-23 PMID: 26845022
- 8. Okada M et al.. 2022. Characterization of glutamate-cysteine ligase and glutathione synthetase from the δ-proteobacterium Myxococcus xanthus.. Proteins 90(8):1547-1560 PMID: 35277888
